
- Practical Considerations for Stroke Prevention Across the Continuum
Recognizing the Signs: Identifying Patients at Risk for Recurrent Stroke or TIA
Key Takeaways
- Early post-TIA risk is clinically meaningful (≈2.4% at 48 hours; ≈3.8% at 7 days), supporting urgent assessment rather than reassurance when symptoms resolve.
- Etiology-driven workup should be verified and completed, with attention to symptomatic stenosis, acute infarct on imaging, recurrent focal deficits, and newly detected atrial fibrillation.
Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.
This content was independently produced by Pharmacy Times in partnership with Bayer HealthCare.
Stroke survivors face an ongoing threat of another cerebrovascular event. According to the CDC, nearly 1 in 4 strokes in the United States occur in people with a previous stroke.1 Recognizing patients at risk requires attention to new neurologic symptoms and gaps in long-term prevention. Pharmacists can help by identifying uncontrolled risk factors, reviewing medications, and reinforcing when patients should seek emergency care.
Understanding Recurrence Risk
The days immediately after a transient ischemic attack (TIA) warrant particular attention. A systematic review and meta-analysis estimated ischemic stroke risk after TIA at 2.4% within 2 days and 3.8% within 7 days.2 These pooled estimates span different populations and treatment eras; they are not an individualized prediction. They nevertheless reinforce the need for prompt assessment rather than reassurance when symptoms resolve.
Risk also persists beyond the initial event. A 2026 meta-analysis of cohorts followed for at least 1 year after TIA or minor stroke identified older age, previous stroke or TIA, atrial fibrillation (AF), hypertension, diabetes, ischemic heart disease, and smoking as markers of higher subsequent stroke risk.3 These findings support continued attention to prevention after the early recovery period.
Clinical Markers and Screening Approaches
Assessment should begin with the cause of the index event. The American Heart Association/American Stroke Association secondary prevention guideline recommends a diagnostic evaluation to guide treatment, including brain and vascular imaging, electrocardiography, laboratory assessment, and selective use of echocardiography and longer-term rhythm monitoring.4 Pharmacists reviewing the record should determine whether the mechanism is established and whether recommended testing remains outstanding.
Particular concerns include recurrent or increasing episodes of focal neurologic symptoms, an acute infarct on imaging, symptomatic arterial stenosis, and newly identified AF.5 These findings require timely clinical review. The ABCD2 score can contribute to TIA risk assessment, but it does not capture all high-risk mechanisms or imaging findings. A low score should not be used alone to defer urgent evaluation.5
For patients without new symptoms, a practical medication review can identify missed refills, persistently elevated blood pressure, tobacco use, or a low-density lipoprotein cholesterol (LDL-C) level above the treatment goal. These findings should prompt discussion with the treating team about barriers to prevention and the need for follow-up.
Modifiable Cardiovascular Risk Factors
Blood pressure control remains a priority. For most patients with hypertension after stroke or TIA, an office blood pressure goal below 130/80 mm Hg is recommended for ongoing prevention.4 Pharmacists can review home readings, adherence, adverse effects (AEs), and whether the regimen is achieving the individualized goal.
Lipid management should be guided by atherosclerotic cardiovascular disease (ASCVD) risk. The 2026 multisociety dyslipidemia guideline recommends high-intensity statin therapy for patients with clinical ASCVD, with an LDL-C goal below 55 mg/dL for those at very high risk and below 70 mg/dL for those not at very high risk. Nonstatin therapy may be needed when maximally tolerated statin treatment does not achieve the appropriate goal.6 Pharmacists should confirm the patient’s risk category rather than apply a single LDL-C target to every stroke survivor.
Diabetes management also requires individualization. Glycemic goals should account for hypoglycemia risk, comorbidities, and patient preferences. Achieving a hemoglobin A1c of 7% or lower has not been established to independently prevent recurrent stroke. Glucose-lowering therapies with demonstrated cardiovascular benefit should be considered as part of the treatment plan when appropriate.4
AF deserves special attention because identifying a cardiac embolic source changes prevention. Oral anticoagulation is generally indicated after ischemic stroke or TIA in patients with AF unless contraindicated. For noncardioembolic ischemic stroke or TIA, antiplatelet therapy is recommended rather than anticoagulation.4 Pharmacists should verify that the antithrombotic regimen matches the documented indication and review interactions, bleeding concerns, and adherence.
Lifestyle counseling remains essential. Smoking cessation, safe activity adapted to functional ability, and a Mediterranean-style dietary pattern are encouraged.4 Guidelines suggest that patients with stroke or TIA and hypertension who do not already limit salt cut sodium by at least 1 g/d. Men who have more than 2 alcoholic drinks per day and women who have more than 1 should be counseled to reduce or eliminate intake.4 Small, specific goals can make these discussions more manageable during follow-up.
The Pharmacist’s Role in Counseling and Secondary Prevention
Medication counseling should address why each preventive therapy is prescribed and what makes it difficult to take. Ask about affordability, AEs, swallowing difficulties, and regimen complexity. Refill history, patient reports, and caregiver input can guide a practical plan for adherence and communication with the care team.
Symptom education is equally important: BE FAST highlights sudden Balance loss, Eye or vision changes, Face drooping, Arm weakness, and Speech difficulty, with Time to call 911. Patients and caregivers should call immediately, note symptom onset, and use emergency medical services rather than drive to the hospital. Symptoms that resolve still require urgent evaluation for possible TIA.5,7 Teach-back can help confirm that the patient knows what action to take.
At subsequent visits, pharmacists can revisit patient blood pressure and lipid goals, medication access, tobacco use, and completion of recommended testing. Ongoing communication with primary care and stroke specialists helps keep prevention priorities visible.
Conclusion
Recurrent stroke is often preceded by warning signs that are easy to miss: a lapsed refill, a blood pressure reading above goal, an antithrombotic that does not match the documented mechanism, or a brief episode the patient never reported. Each routine encounter is a chance to catch one of them. A pharmacist who checks these at every visit and asks directly about new or passing neurologic symptoms can close gaps that the formal follow-up schedule may not reach.
REFERENCES
Stroke facts. CDC. October 24, 2024. Accessed September 26, 2026. https://www.cdc.gov/stroke/data-research/facts-stats/index.html
Shahjouei S, Sadighi A, Chaudhary D, et al. A 5-decade analysis of incidence trends of ischemic stroke after transient ischemic attack: a systematic review and meta-analysis. JAMA Neurol. 2021;78(1):77-87. doi:10.1001/jamaneurol.2020.3627
Khan F, Yogendrakumar V, Lun R, et al. Prognostic factors for long-term risk of stroke after transient ischemic attack or minor stroke: a systematic review and meta-analysis. Circulation. 2026;153(17):1281-1295. doi:10.1161/CIRCULATIONAHA.125.078763
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375
Amin HP, Madsen TE, Bravata DM, et al; American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease. Diagnosis, workup, risk reduction of transient ischemic attack in the emergency department setting: a scientific statement from the American Heart Association. Stroke. 2023;54(3):e109-e121. doi:10.1161/STR.0000000000000418
Writing Committee Members; Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423
Signs and symptoms of stroke. CDC. May 19, 2026. Accessed September 26, 2026. https://www.cdc.gov/stroke/signs-symptoms/index.html
Articles in this issue
Related to this article








